Scopus BioPharma Inc.
SCPS
Rank in Stocks
#34314
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical... Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Share Price
$0.0004
Last synced: 2026-11-09
Market Cap
$16.83K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Scopus BioPharma Inc. (SCPS)
Category
Healthcare
EPS for Scopus BioPharma Inc. (SCPS)
EPS as of June 2023 TTM: $-0.32
According to Scopus BioPharma Inc.'s latest financial reports, its current EPS (TTM) is $-0.32. At the end of 2022 the company had an EPS of $-0.55, an increase over its 2021 EPS of $-1.61.
EPS history for Scopus BioPharma Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.32 | -41.82% |
| 2022 | $-0.55 | -65.84% |
| 2021 | $-1.61 | 85.06% |
| 2020 | $-0.87 | 383.33% |
| 2019 | $-0.18 | 293.01% |
| 2018 | $-0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,993.75% |
US
|
|
| $-7.07 | 2,109.38% |
US
|
|
| $-5.29 | 1,553.13% |
AU
|
|
| $12.88 | -4,125.03% |
BE
|
|
| $21.56 | -6,837.50% |
NL
|
Questions about Scopus BioPharma Inc.'s earnings per share (EPS)
What is Scopus BioPharma Inc.'s earnings per share (EPS)?
Scopus BioPharma Inc.'s earnings per share (EPS) over the last twelve months is $-0.32, as of Jun 2023.
What was Scopus BioPharma Inc.'s earnings per share (EPS) in 2022?
In 2022, Scopus BioPharma Inc.'s earnings per share (EPS) was $-0.55, compared with $-1.61 in 2021.
How has Scopus BioPharma Inc.'s earnings per share (EPS) changed since 2018?
From 2018 to 2022, Scopus BioPharma Inc.'s earnings per share (EPS) was highest in 2018 ($-0.05) and lowest in 2021 ($-1.61).
How does Scopus BioPharma Inc.'s earnings per share (EPS) compare with similar companies?
Scopus BioPharma Inc.'s earnings per share (EPS) ($-0.32) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.